Table I: Frequency of IL-1Ra VNTR polymorphism in biopsy-proven erythema nodosum (EN) patients and controls from northwestern Spain*.

<table>
<thead>
<tr>
<th>Allele</th>
<th>Controls*</th>
<th>EN Total*</th>
<th>EN Idiopathic</th>
<th>EN Secondary</th>
<th>EN due to Sarcoidosis</th>
<th>EN secondary to other conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>109 (%)</td>
<td>101 (%)</td>
<td>36 (%)</td>
<td>65 (%)</td>
<td>31 (%)</td>
<td>34 (%)</td>
</tr>
<tr>
<td>2</td>
<td>61 (28%)</td>
<td>61 (30%)</td>
<td>20 (28%)</td>
<td>41 (32%)</td>
<td>16 (26%)</td>
<td>25 (37%)</td>
</tr>
<tr>
<td>Genotype</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>59 (54%)</td>
<td>50 (49%)</td>
<td>19 (53%)</td>
<td>31 (48%)</td>
<td>16 (52%)</td>
<td>15 (44%)</td>
</tr>
<tr>
<td>12</td>
<td>39 (36%)</td>
<td>41 (41%)</td>
<td>14 (39%)</td>
<td>27 (41%)</td>
<td>14 (45%)</td>
<td>13 (38%)</td>
</tr>
<tr>
<td>22</td>
<td>11 (10%)</td>
<td>10 (10%)</td>
<td>3 (8%)</td>
<td>7 (11%)</td>
<td>1 (3%)</td>
<td>6 (18%)</td>
</tr>
</tbody>
</table>

*No statistically significant differences between the whole group of EN patients and controls were found.

References:
Letters to the Editors


